Propanc Biopharma (OTCMKTS:PPCB) Shares Up 20.6% – Still a Buy?

Propanc Biopharma Inc (OTCMKTS:PPCB) shares shot up 20.6% during trading on Monday . The company traded as high as $2.35 and last traded at $2.05. 297,311 shares changed hands during mid-day trading, an increase of 148% from the average session volume of 119,765 shares. The stock had previously closed at $1.70.

Propanc Biopharma Trading Up 20.6%

The firm has a market cap of $32.51 million, a P/E ratio of -0.16 and a beta of 3.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.24 and a quick ratio of 2.24. The stock has a 50 day moving average of $0.15 and a 200 day moving average of $0.42.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC bought a new stake in Propanc Biopharma Inc (OTCMKTS:PPCB) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.33% of Propanc Biopharma as of its most recent SEC filing.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.